Significant progress in development with design freeze expected in June
Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, notes the Press Release issued today by UK Rapid Test Consortium (“UK-RTC”) on developing a COVID-19 lateral flow antibody test (“COVID-19 Rapid Test”) that can be used by people in their homes.
As announced on 9 April 2020, the Company signed a Memorandum of Understanding (“MOU”) with Abingdon Health Limited, BBI Solutions Limited, CIGA Healthcare Limited, in conjunction with the University of Oxford to form the UK-RTC in order to jointly develop and manufacture a COVID-19 Rapid Test as part of the Government’s five pillar national testing strategy for COVID-19.
As lead partner of the UK-RTC, Abingdon Health Limited has been developing the COVID-19 Rapid Test and the Company notes the significant progress made to date in such a short period of time. The Company’s role as a member of the UK-RTC is unchanged in that it is providing development support where required and will provide volume manufacturing capacity of the COVID-19 Rapid Test once design freeze has been attained by Abingdon Health and they have successfully transferred the manufacturing protocols to the Company.
Omega will provide a further update once design freeze of the COVID-19 Rapid Test has been reached, a key milestone that the consortium hopes will be attained in June.
The UK-RTC Press Release is provided in full at the end of this announcement.
Colin King, CEO of Omega commented: “I am really impressed with the progress Abingdon have made to date with the development in such a short period of time. Everyone is working extremely hard to deliver a high-quality product as soon as possible to help play a part in returning life back to more normal levels in the UK. ”
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned